FOLH1 and Familial prostate cancer: PSMA PET allows the detection of small lymph node metastases even in men with early prostate-specific antigen (PSA) value progression (≤0.5 ng/mL), resulting in improved patient selection and the early diagnosis of nodal oligorecurrent prostate cancer [8,9].